KN-002 is under clinical development by Kinaset Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect KN-002’s likelihood of approval (LoA) and phase transition for Asthma took place on 06 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their KN-002 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

KN-002 overview

KN-002(formerly known as VR-588) is under development for the treatment of severe inflammatory airway diseases including asthma, chronic obstructive pulmonary disease (COPD) and other unspecified disease. It is a small molecule administered by inhalation. The drug candidate is a selective pan-JAK inhibitor. It act by targeting JAK1, JAK2, JAK3 and tyrosine kinase 2

Kinaset Therapeutics overview

Kinaset Therapeutics is a biopharma company developing novel respiratory therapeutics. It is headquartered in Medfield, Massachusetts, the US.

Quick View KN-002 LOA Data

Report Segments
  • Innovator
Drug Name
  • KN-002
Administration Pathway
  • Inhalational
Therapeutic Areas
  • Respiratory
  • Undisclosed
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.